Single Center, Randomized, Open-label, 5-fold Crossover Study in Healthy Male Subjects to Investigate the Pharmacokinetic Dose Proportionality of BAY94-8862 Given as 5 Different Single Oral IR Tablet Doses (1.25, 2.5, 5.0, 7.5 and 10 mg)
Phase of Trial: Phase I
Latest Information Update: 09 Jan 2013
At a glance
- Drugs Finerenone (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Sep 2012 New trial record
- 01 Sep 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.